


# Integrated Research Limited (IRI) FY2021 Annual Financial Results

19 August 2021

John Ruthven, CEO Peter Adams, CFO







# Agenda

3	Section 1 – Results Analysis
14	Section 2 – Transition and Growth Strategy
25	Appendix

IR's transition to a SaaS model is underway, with higher quality subscription revenues and greater leverage to long term growth trends



# Section 1 – Results Analysis






# CEO key messages

ii•

Executing transition strategy to a SaaS subscription model, improved 2H performance


- 1. Transitioning to higher quality, growing SaaS subscription-based revenues
- 2. FY21 results impacted by deal deferrals and cautious buyer behaviour in 1H
  - Revenue down 29%, NPAT in constant currency down 51%
- 3. Execution of 4-point recovery plan drives improved 2H performance
  - Sales execution, accelerate product roadmap to SaaS, cost management and resourcing.
  - 2H revenue +30% v 1H, NPAT in constant currency + 210%, solid cash flow
- 4. IR is strategically well positioned to capitalise on positive growth trends in remote working and cashless payments and build share in expanded \$1.2B TAM.






# Full-year performance review (A\$M) New product launches and sales execution drive 2H recovery following weak 1H










# 2H FY21 Results (A\$M)

ii•

Improved 2H performance - revenue and profit recovery








Note: growth metrics represent FY21 2H vs FY21 1H

# Transition underway Executing clear plan to transition to higher quality growing SaaS based subscription revenues





# FY21 progress report Delivering product and platform to support SaaS growth

Customer growth retention	&	SaaS customer acquisition		Product innovation		Transition to subscription	
>100 renewal & capacity deals in H2	2	On-board strategic foundational platform customers	<b>~</b>	Coverage of the 3 largest cloud collaboration vendors	<b>~</b>	Reliable and predictable revenue streams	WIP
>40 new customers	27	20+ customers	5	Entry into Real-Time Payments market	WIP	Flex-licensing to support customer journey	<b>~</b>
Customer success managers	<b>~</b>	Grow ARR base (revenue backlog)	<b>~</b>	Revamped Product Management Leadership	<b>~</b>	Back-office system & process readiness	WIP



ii•

Proforma subscription revenue and cash receipts steady in US dollars

Annual results (statutory)	Jun 2021	Jun 2020	% change
	A\$M	A\$M	
Revenue from licence fees	47.4	72.1	(34%)
Revenue from maintenance fees	18.1	23.9	(24%)
Revenue from subscription fees	0.3	0.7	(55%)
Revenue from testing solution services	4.3	5.5	(22%)
Revenue from professional services	8.4	8.6	(3%)
Total revenue	78.5	110.9	(29%)
Revenue in constant currency*	85.8	110.9	(23%)
Proforma subscription revenue in USD	US\$52.1	US\$53.9	(3%)
Proforma revenue in USD*	US\$62.5	US\$66.2	(6%)
Cash receipts from customers in USD**	US\$58.9	US\$58.9	0%


non-statutory measure; refer appendix for reconciliation of statutory revenue to proforma revenue to no debtor factoring in FY21 (prior year debtor factoring excluded to enable comparison)

# Geographic and Product revenue analysis





Subscription revenue; stable performance in US dollars





# Collaborate \$M 70 60 50 40 20 10 2015 2016 2017 2018 2019 2020 2021 Proforma subscription AUD Proforma subscription USD Statutory AUD







Investment in product development to expand addressable market and leverage to growth trends


Annual results	Jun 2021	Jun 2020	% change
	A\$M	A\$M	
Gross research and development spend	21.3	22.5	(6%)
Capitalisation of development expenses	(12.0)	(14.0)	(14%)
Amortisation of capitalised expenses	9.8	8.8	11%
Research and development (net)	19.1	17.4	10%
Sales, professional services and marketing	43.4	54.6	(20%)
General and administration	6.2	6.2	0%
Total operating expenditure	68.7	78.2	(12%)
Net other losses (eg foreign currency revaluation)	(1.3)	(1.9)	(30%)
Expenditure in constant currency	71.7	78.2	(8%)
Gross development spend : revenue	27%	20%	



### **Development Costs**

- Innovation agenda maintained
- Spend mostly geared to SaaS platform and new products

# Net cash flow analysis Positive operating cash flow funds growth investments





No debtor

## Balance sheet

ii•

Increased net cash

Strong balance sheet – net cash \$5.5M


Trade receivables - strong source of future cash

Undrawn debt facility of \$14.7M

	Jun 21	Jun 20
	A\$M	A\$M
Cash and cash equivalents	12.1	9.7
Trade and other receivables	79.5	87.3
Intangible Assets	30.0	29.1
Right-of-use Assets	6.0	6.4
All Other Assets	7.5	7.4
Total Assets	135.1	139.8
Trade and other liabilities	10.2	10.2
Borrowings	6.7	5.0
Provisions	4.7	4.6
Tax liabilities	7.2	8.6
Deferred revenue	16.4	22.3
Lease and other liabilities	6.5	6.6
Total liabilities	51.7	57.3
Net assets	83.3	82.5




# Section 2 - Transition and Growth Strategy



# Platform approach to product innovation Drives Access to Larger Market Opportunity

il






# Product strategy



New product launches expand addressable market and leverage to long term growth trends



# Accelerated move to cashless payments



IR is well placed to benefit from cards growth and new real-time payments

Traditional payment market disrupted by emerging payment methods and Fintechs Cashless payments rising on the back of pandemic related dynamics New standards drive need for updated High-value and Real-time solutions

	Market		Opportunity		
Global Non-Cash	737B	11.5%	Card Payments	Provide payment-related analytics to enterprises and banks  Provide to a broader range of user types within new and existing customers	
Transactions (excl. cheques)	Payments transactions	CAGR	Real-Time Payments	Launch of new High Value product line, and upcoming Real Time Payments product  Provide monitoring and analytics tools to provide real-time insights to customers	

Source: Capgemini World Payments Report 2020





IR well placed to leverage trend to 'Hybrid Work'

- 'Hybrid Working' increases UC system complexity and further exposes UC challenges
   Industry specific video applications (e.g. Healthcare) are increasing the mission critical nature of UCaaS
- Vendors and carriers partnering to integrate carrier telephony with UCaaS at scale
- Growth in video enabled collaboration spaces is accelerating higher expectations on user experience

		Market <sup>1</sup>		Opportunity		
<b>D</b>	550M	185M conferencing users	48% Growth 2020	On- premises	Cisco opportunity increases as IR is the recommended replacement for Cisco's endof-sale UC monitoring tool  Demand for our Avaya solutions remains strong with existing customers	
	UC users		7% CAGR (2021-25)	Cloud	MS Teams, Zoom & Webex solutions targeting net-new and cross sell  Upcoming telephony support in the cloud creates strong differentiation and value for enterprise & service provider	

1. Source: Gartner UC Market Forecast 2Q21 – Jun 2021



Long-term, high value relationships based on mission critical solutions














Clear execution priorities to accelerate transition benefits

Sales	Product & Development	Business Support
Implement go-to-market changes to increase new business sales with a Focus Accounts territory model	Deliver new products & enhancements to extend our customer value proposition	Manage the Transform IR, a comprehensive company-wide change management program
Implement CX360, a program to enable the sales team & increase field productivity	Adopt a build vs buy vs partner strategy, to accelerate time to market in key portfolio areas	'Unitise' the business in support of the transition of the business model; including business reporting
Accelerate demand generation & pipeline build through increased program spend & SDRs	Increase product velocity with augmentation and using cloud native services to allow focus on differentiating capabilities and thought leadership	Implement key reward & recognition initiatives to retain staff in a highly competitive market

# FY22 Key Performance Indicators New customers and product launches support transition to SaaS growth


Customer growth & retention		New customer acquisition		Product innovation		Business Model Transition	
TCV from new products & capacity to existing customers	20%	New customers	75	Percent of TCV from products released in the last 5 years	15%	Growth in cloud deferred revenue backlog	100%
Proforma subscription Revenue retention	92%	TCV from new customers	30%	Extend 3 <sup>rd</sup> party strategic relationships		Systems & process readiness to report SaaS metrics	
Customer retention	95%			Development spend to TCV	14%		




## Conclusions

il•

- Transition is underway executing plan to grow higher quality, SaaS based subscription revenues
- 2. Recovery in 2H results, with revenue and profit growth
- 3. New product launches expand addressable market opportunities
- Increasing leverage to long term growth trends in cashless payments and remote working









**Disclaimer** 

## Disclaimer



### **SUMMARY INFORMATION**

This document and the associated transcript (together "the presentation") has been prepared by Integrated Research Limited (ABN 76 003 588 449) (IRI). The presentation provides general background Information about IRI's activities current at the date of preparation. IRI is not responsible for updating, and does not undertake to update, the presentation. It contains information in a summary form and does not purport to be complete. It should be read in conjunction with IRI's other announcements released to ASX (available at www.asx.com au).

### **NOT INVESTMENT ADVICE**

The information contained in the presentation does not constitute investment or financial product advice or a recommendation to acquire shares or other financial products. It does not take into account the investment objectives, financial situation or needs of any particular investor. Investors should consider these factors, with professional advice if appropriate, before making an investment decision.

### FINANCIAL INFORMATION

All dollar values are in Australian Dollars (A\$) unless stated otherwise. All financial information is presented in respect of the year ended 30 June 2021 unless stated otherwise. The presentation contains certain non-IFRS financial measures that IRI believes is relevant and appropriate to understanding its business. The presentation uses proforma subscription revenue, which is used consistently without bias year on year for comparability and to present a clear view of underlying results. The basis of preparation and a reconciliation to statutory results is provided in the appendix to this presentation. A number of figures, amounts and percentages in the presentation are subject to the effect of rounding.

### FORWARD LOOKING STATEMENTS

The presentation contains certain "forward-looking statements". The words "anticipate", "believe", "expect", "project", "forecast", "estimate", "likely", "intend", "should", "could", "may", "target", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. While due care and attention has been used in the preparation of forward-looking statements, they are not guarantees of future performance and involve known and unknown risks. uncertainties, assumptions and other factors, some of which are beyond the control of IRI, that may cause actual results, conduct, performance or achievements to differ materially from those expressed or implied in such statements. There can be no assurance that the actual outcomes will not differ materially from these statements. You are cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the outbreak of COVID-19. Neither IRI nor any other person gives any representation, warranty, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in the presentation will actually occur. All forward looking statements in the presentation reflect views only as at the date of this presentation. Except as required by applicable law or the ASX Listing Rules, IRI disclaims any obligation or undertaking to publicly update any forward-looking statements, whether as a result of new information or future events or otherwise.

### **PAST PERFORMANCE**

Statements about past performance are not necessarily indicative of and should not be relied upon as an indication of, future performance.

### **NOT AN OFFER**


The presentation is for information purposes only and is not a prospectus, product disclosure statement or other disclosure or offering document under any law. The presentation does not constitute or contain an offer, invitation, solicitation, recommendation, advice or recommendation with respect to issue, purchase, or sale of any shares or financial products in any jurisdiction. The presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to any 'US person' (as defined in Regulation S under the US Securities Act of 1933, as amended (Securities Act) (US Person)). Securities may not be offered or sold in the United States or to US Persons absent registration or an exemption from registration. IRI shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or jurisdiction of the United States.

### **GENERAL**

Each of IRI, its related bodies corporate and their respective affiliates, officers, employees, agents and advisers, to the maximum extent permitted by law, expressly disclaim any and all liability in respect of any expenses, losses, damages or costs (including indirect or consequential loss) arising from or in connection with this presentation or the information contained in or omitted from it, including, without limitation, any liability arising from fault, negligence or otherwise. No representation or warranty, express or implied, is made as to the fairness, currency, accuracy, reliability or completeness of information contained in the presentation. The information in the presentation remains subject to change without notice.



**Appendix** 





## Who we are

IR

IR is the leading global provider of performance management and analytics for enterprise communications, collaboration, and payment systems

## What we do

### Capabilities

IR provides best in class performance management across collaboration and payments transactions ecosystems, cloud, hybrid or on-premises

# Why customers buy

### **Value Proposition**

IR solutions simplify the complexity of modern technologies by optimising business-critical systems and processes through real-time insights in a connected world

## Why we succeed

### **Competitive Advantage**


The IR Prognosis hybrid-cloud platform is purpose built for the demands of real-time, complex, high-volume data.

IR has 25% of the Fortune 500 as customers

## Go-to-market model

Customer "high touch" model





# Platform approach to product innovation



Solutions

### Collaborate



End user experience monitoring
UC application monitoring
Network Troubleshooting

### **Transact**



Card Transactions

Payments Application Health

### Infrastructure



Hardware
Operating System

Virtualization





### **Platform Capabilities**

Common services architected for product-line and/or portfolio-wide use to streamline product delivery



### Cloud connectors

Connect & Interact with other cloud services



### **Edge connectors**

Intelligent Edge Capabilities deployed on-premise



### **Prognosis Cloud**

Rapid delivery of new capabilities and products



### **Prognosis Server**

Continue serving customers with hybrid delivery of features





# Proforma subscription revenue

## Purpose:

To provide an alternate view of underlying performance by restating term licence and maintenance revenues on a recurring subscription basis

### How:

- All licence sales from FY2012 to FY2021 were analysed for each region in their natural currencies (the historic analysis period)
- Perpetual deals have been reported separately in the year sold
- Subscription revenues have been calculated by aggregating amortised licence revenues with maintenance revenues for each product line
- Other revenue streams have been reported the same as the statutory accounts (e.g. professional services and testing services)

A reconciliation of proforma revenues and statutory revenue has been included for the reporting period

# Proforma subscription revenue



Annual revenue	FY19	FY20	FY21	FY19	FY20	FY21
	A\$M	A\$M	A\$M			
Infrastructure	20.3	21.5	18.3	3%	6%	-15%
Transact	8.4	10.5	10.0	28%	25%	-5%
Collaborate	45.2	49.3	41.4	20%	9%	-16%
Proforma subscription revenue	73.8	81.3	69.6	16%	10%	-14%
15						
Perpetual sales	2.9	4.3	1.2	62%	51%	-73%
Testing Services	5.0	5.5	4.3	-4%	11%	-22%
Professional Services	7.4	8.6	8.4	0%	17%	-3%
Proforma revenue	89.1	99.8	83.5	14%	12%	-16%
Statutory revenue	100.8	110.9	78.5	11%	10%	-29%
Reconciliation to Statutory Accounts:						
Proforma revenue	89.1	99.8	83.5			
Deduct Amortised licence fees	-48.3	-56.5	-51.2			
Add Licence fees recognised upfront	60.0	67.6	46.2			
Statutory revenue	100.8	110.9	78.5			

# Cash flow



FY21	FY20	Change
A\$M	A\$M	
78.8	88.8	(11%)
-	7.6	(100%)
78.8	96.4	(18%)
0.6	-	
(55.1)	(66.0)	(17%)
24.3	30.3	(20%)
(3.2)	(6.2)	(48%)
21.1	24.2	(13%)
(10.8)	(14.2)	(24%)
(7.1)	(9.7)	(27%)
3.2	0.2	1500%
9.7	9.3	4%
(0.8)	0.2	
12.1	9.7	25%
	78.8  78.8  0.6 (55.1) 24.3 (3.2) 21.1  (10.8)  (7.1)  3.2  9.7 (0.8)	A\$M       A\$M         78.8       88.8         -       7.6         78.8       96.4         0.6       -         (55.1)       (66.0)         24.3       30.3         (3.2)       (6.2)         21.1       24.2         (10.8)       (14.2)         3.2       0.2         9.7       9.3         (0.8)       0.2

# Financial track record



Jun-12	Jun-13	Jun-14	Jun-15	Jun-16	Jun-17	Jun-18	Jun-19	Jun-20	Jun-21
28.9	26.6	28.0	41.0	45.7	53.4	52.6	62.8	72.1	47.4
48.6	48.9	53.2	70.3	84.5	91.2	91.2	100.8	110.9	78.5
11.1	11.1	10.3	19.0	21.4	25.7	25.8	28.9	30.9	8.5
23%	23%	19%	27%	25%	28%	28%	29%	28%	11%
18.5	18.6	17.8	28.1	32.0	37.0	36.2	40.2	42.9	21.9
38%	38%	33%	40%	38%	41%	40%	40%	39%	28%
9.0	9.1	8.5	14.3	16.0	18.5	19.1	21.9	24.1	7.9
19%	19%	16%	20%	19%	20%	21%	22%	22%	10%
5.41	5.40	5.03	8.41	9.42	10.86	11.19	12.72	14.00	4.61
5.00	5.00	5.00	7.50	6.50	6.50	6.50	7.25	7.25	-
92%	93%	99%	89%	69%	60%	58%	57%	50%	n/a_
31%	30%	28%	39%	39%	38%	33%	31%	29%	10%
15%	(8%)	5%	46%	11%	17%	(2%)	19%	15%	(34%)
9%	1%	9%	32%	20%	8%	0%	11%	10%	(29%)
19%	1%	(8%)	85%	13%	20%	1%	12%	7%	(73%)
17%	0%	(4%)	58%	14%	16%	(2%)	11%	7%	(49%)
21%	0%	(6%)	68%	12%	16%	3%	14%	10%	(67%)
	28.9 48.6 11.1 23% 18.5 38% 9.0 19% 5.41 5.00 92% 31% 15% 9% 19% 17%	28.9       26.6         48.6       48.9         11.1       11.1         23%       23%         18.5       18.6         38%       38%         9.0       9.1         19%       19%         5.41       5.40         5.00       5.00         92%       93%         31%       30%         15%       (8%)         9%       1%         19%       1%         17%       0%	28.9       26.6       28.0         48.6       48.9       53.2         11.1       11.1       10.3         23%       23%       19%         18.5       18.6       17.8         38%       38%       33%         9.0       9.1       8.5         19%       19%       16%         5.41       5.40       5.03         5.00       5.00       5.00         92%       93%       99%         31%       30%       28%         15%       (8%)       5%         9%       1%       9%         19%       1%       (8%)         17%       0%       (4%)	28.9       26.6       28.0       41.0         48.6       48.9       53.2       70.3         11.1       11.1       10.3       19.0         23%       23%       19%       27%         18.5       18.6       17.8       28.1         38%       38%       33%       40%         9.0       9.1       8.5       14.3         19%       19%       16%       20%         5.41       5.40       5.03       8.41         5.00       5.00       5.00       7.50         92%       93%       99%       89%         31%       30%       28%       39%         15%       (8%)       5%       46%         9%       1%       9%       32%         19%       1%       (8%)       85%         17%       0%       (4%)       58%	28.9       26.6       28.0       41.0       45.7         48.6       48.9       53.2       70.3       84.5         11.1       11.1       10.3       19.0       21.4         23%       23%       19%       27%       25%         18.5       18.6       17.8       28.1       32.0         38%       38%       33%       40%       38%         9.0       9.1       8.5       14.3       16.0         19%       19%       16%       20%       19%         5.41       5.40       5.03       8.41       9.42         5.00       5.00       5.00       7.50       6.50         92%       93%       99%       89%       69%         31%       30%       28%       39%       39%         15%       (8%)       5%       46%       11%         9%       1%       9%       32%       20%         19%       1%       (8%)       85%       13%         17%       0%       (4%)       58%       14%	28.9         26.6         28.0         41.0         45.7         53.4           48.6         48.9         53.2         70.3         84.5         91.2           11.1         11.1         10.3         19.0         21.4         25.7           23%         23%         19%         27%         25%         28%           18.5         18.6         17.8         28.1         32.0         37.0           38%         38%         33%         40%         38%         41%           9.0         9.1         8.5         14.3         16.0         18.5           19%         19%         16%         20%         19%         20%           5.41         5.40         5.03         8.41         9.42         10.86           5.00         5.00         5.00         7.50         6.50         6.50           92%         93%         99%         89%         69%         60%           31%         30%         28%         39%         39%         38%           15%         (8%)         5%         46%         11%         17%           9%         1%         9%         32%         20%	28.9         26.6         28.0         41.0         45.7         53.4         52.6           48.6         48.9         53.2         70.3         84.5         91.2         91.2           11.1         11.1         10.3         19.0         21.4         25.7         25.8           23%         23%         19%         27%         25%         28%         28%           18.5         18.6         17.8         28.1         32.0         37.0         36.2           38%         38%         33%         40%         38%         41%         40%           9.0         9.1         8.5         14.3         16.0         18.5         19.1           19%         19%         16%         20%         19%         20%         21%           5.41         5.40         5.03         8.41         9.42         10.86         11.19           5.00         5.00         5.00         7.50         6.50         6.50         6.50           92%         93%         99%         89%         69%         60%         58%           31%         30%         28%         39%         39%         38%         0%      <	28.9         26.6         28.0         41.0         45.7         53.4         52.6         62.8           48.6         48.9         53.2         70.3         84.5         91.2         91.2         100.8           11.1         11.1         10.3         19.0         21.4         25.7         25.8         28.9           23%         23%         19%         27%         25%         28%         28%         29%           18.5         18.6         17.8         28.1         32.0         37.0         36.2         40.2           38%         38%         33%         40%         38%         41%         40%         40%           9.0         9.1         8.5         14.3         16.0         18.5         19.1         21.9           19%         19%         16%         20%         19%         20%         21%         22%           5.41         5.40         5.03         8.41         9.42         10.86         11.19         12.72           5.00         5.00         5.00         7.50         6.50         6.50         6.50         7.25           92%         93%         99%         89%         69%	28.9         26.6         28.0         41.0         45.7         53.4         52.6         62.8         72.1           48.6         48.9         53.2         70.3         84.5         91.2         91.2         100.8         110.9           11.1         11.1         10.3         19.0         21.4         25.7         25.8         28.9         30.9           23%         23%         19%         27%         25%         28%         28%         29%         28%           18.5         18.6         17.8         28.1         32.0         37.0         36.2         40.2         42.9           38%         38%         33%         40%         38%         41%         40%         40%         39%           9.0         9.1         8.5         14.3         16.0         18.5         19.1         21.9         24.1           19%         19%         20%         21%         22%         22%           5.41         5.40         5.03         8.41         9.42         10.86         11.19         12.72         14.00           5.00         5.00         7.50         6.50         6.50         6.50         7.25         7.2



<end>

